Early proactive therapeutic drug monitoring with ustekinumab therapy in pediatric Crohn's disease: data from the prospective Canadian children IBD network.

Key Points

• The aim is to evaluate the impact of ustekinumab dosing on therapeutic outcomes in children with Crohn's disease.
• Analyzed ustekinumab dosing in children with Crohn's disease from the Canadian children IBD network.
• Compared drug levels between children under and over 40 kg at week 8.
• Assessed the correlation between week 8 drug levels and later treatment outcomes.
• Children under 40 kg required a higher dose of ustekinumab to achieve similar drug levels compared to those 40 kg and above.
• Higher week 8 ustekinumab levels were linked to better treatment outcomes later on.